Quick Answer
20/20 Biolabs, Inc. reported Diluted EPS of $0.76 per share (loss) for fiscal year 2025.
20/20 Biolabs, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.76 | +34.5% |
| 2024 | -$1.16 | — |
- 20/20 Biolabs, Inc. showed an increase of +34.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2024–2025 period, 20/20 Biolabs, Inc.’s diluted eps has grown by 34.5% (from $1.16 per share (loss) to $0.76 per share (loss)).
- The most recent figure is from 20/20 Biolabs, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: